Applications of toxicogenomics to nonclinical drug development: Regulatory science considerations

Methods in Molecular Biology

Volumn 460, Issue , 2008, Pages 239-261

  Sistare, Frank D ^a   Degeorge, Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biomarker; Critical path; Drug development; Drug safety testing; Genomics; Guidance; Investigative toxicology; Lead optimization; Metabolomics; Proteomics; Qualification; Regulation; Toxicogenomics; Validation

Indexed keywords

ANIMALIA;

EID: 84934434193     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-48-9_12     Document Type: Article

References (30)

1. Schena, M., Shalon, D., Davis, R.W., and Brown, P.O. (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470.
2. Ulrich, R. and Friend, S. (2002) Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat. Rev. Drug Discov. 1, 84-88.
3. Food and Drug Administration. (16 March 2004) Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Available at http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf.
4. European Medicines Agency. (23 March 2004) Evaluation of medicines for human use. Discussion paper. The European Medicines Agency road map to 2010: preparing the ground for the future. Available at http://www.emea.europa.eu/ pdfs/general/direct/directory/3416303en.pdf. Doc Ref: EMEA/H/34163/03/Rev 2.0.
5. European Medicines Agency. (22 March 2007) Evaluation of medicines for human use. Innovative drug development approaches. Final report from the EMEA/CHMP-Think-Tank Group on Innovative Drug Development. Available at http://www.emea.europa.eu/pdfs/human/itf/12731807en.pdf. Doc. Ref. EMEA/127318/2007.
6. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715.
7. Chan, V.S.W. and Theilade, M.D. (2005) The use of toxicogenomic data in risk assessment: a regulatory perspective. Clin. Toxicol. 43, 121-126.
8. Code of Federal Regulations. (2 April 2006) 21 CFR 312.23. Title 21. Food and Drugs, Chapter I. Food and Drug Administration Department of Health and Human Resources, Subchapter D Drugs for Human use, Part 312 Investigational New Drug Application, Subpart B Investigational New Drug Application (IND) Sec. 312.23 IND content and format. Available at http://a257.g.akamaitech.net/7/257/ 2422/26mar20071500/edocket.access.gpo.gov/cfr-2007/aprqtr/pdf/21cfr312.23.pdf.
9. Food and Drug Administration. (1995) Content and format of investigational new drug applications (inds) for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products. Available at http://www.fda.gov/cder/guidance/clin2.pdf.
10. Petricoin, E.F. III, Hackett, J.L., Lesko, L.J., Puri, R.K., Gutman, S.I., Chumakov, K., et al. (2002) Medical applications of microarray technologies: a regulatory science perspective. Nat. Genet. 32, 474- 479.
11. Food and Drug Administration. (March 2005) Guidance for industry pharmacogenomic data submissions. Available at http://www.fda.gov/cder/guidance/ 6400fnl.pdf.
12. European Medicines Agency. (April 2006) Guideline on Pharmacogenetics Briefing Meetings. Available at http://www.emea.europa.eu/pdfs/human/ pharmacogenetics/2022704en.pdf.
13. European Medicines Agency. (January 2007) Workplan for the Safety Working Party. Available at http://www.emea.europa.eu/pdfs/human/swp/15242006en.pdf.
14. Food and Drug Administration. (2006) Recommendations for the generation and submission of genomic data. Available at http://www.fda.gov/cder/genomics/ conceptpaper-20061107.pdf.
15. Lesko, L.J., Salerno, R.A., Spear, B.B., Anderson, D.C., Anderson, T., Brazell, C., et al. (2003) Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the First FDA-PhRMA-DruSafe-PWG Workshop, J. Clin. Pharmacol. 43, 342-358.
16. Wagner, J.A., Williams, S.A., and Webster, C.J. (2007) Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. 81, 104-107.
17. Ellinger-Ziegelbauer, H., Stuart, B., Wahle, B., Bomann, W., and Ahr, H.-J. (2004) Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol. Sci. 77, 19-34.
18. Nantermet, P.V., Xu, J., Yu, Y., Hodor, P., Holder, D., Adamski, S., et al. (2004) Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. J. Biol.Chem. 279, 1310-1322.
19. Kramer, J., Curtiss, S., Kolaja, K., Alden, C., Blomme, E., and Curtiss, W., et al. (2004) Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem. Res. Toxicol. 17, 463-470.
20. Food and Drug Administration. (May 2001) Guidance for reviewers pharmacology/toxicology review format. Available at http://www.fda.gov/cder/ guidance/4120fnl.pdf.
21. Code of Federal Regulations. (26 March 2007) 21 CFR 314.50. Title 21 Food and Drugs, Chapter I Food and Drug Administration Department of Health and Human Resources, Subchapter D Drugs for Human use, Part 314 Applications for FDA Approval to Market a New Drug, Subpart B Applications Sec. 314.50 Content and format of an application. Available at http://a257.g.akamaitech.net/7/257/2422/ 26mar20071500/edocket.access.gpo.gov/cfr-2007/aprqtr/pdf/21cfr314.50.pdf.
22. Wong, J.S. and Gill, S.S. (2002) Gene expression changes induced in mouse liver by di(2-ethylhexyl) phthalate. Toxicol. Appl. Pharmacol. 185,180-196.
23. Williams, S.A., Slavin, D.E., Wagner, J.A., and Webster, C. (2006) A costeffectiveness approach to the qualification and acceptance of biomarkers. Nat. Rev. Drug Discov. 5, 897-902.
24. Goodsaid, F. and Frueh, F. (2006) Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7, 773-782.
25. Bulera, S.J., Eddy, S.M., Ferguson, E., Jatkoe, T.A., Reindel, J.F., Bleavins, M.R., and DeLaIglesia, F.A.. (2001)RNAexpression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays. Hepatology 33, 1239-1258.
26. Hamadeh, H.K., Bushel, P.R., Jayadev, S., Martin, K., DiSorbo, O., Sieber, S., et al. (2002) Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. 67, 219-231.
27. Hamadeh, H.K., Bushel, P.R., Jayadev, S., DiSorbo, O., Bennett, L., Li, L., et al. (2002) Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 67, 232-240.
28. Thomas, R.S., Rank, D.R., Penn, S.G., Zastrow, G.M., Hayes, K.R., Pande, K., et al. (2001) Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. 60, 1189-1194.
29. Waring, J.F., Jolly, R.A., Ciurlionis, R., Lum, P.Y., Praestgaard, J.T., Morfitt, D.C., et al. (2001) Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175, 28-42.
30. Sistare, F.D. and Vonderscher, J. (2007) Impact on drug development and regulatory review of the qualification of novel biomarkers of nephrotoxicity. Toxicologist 96, 444.